Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20838327 | 0.86 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL21318254 | 0.86 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL21448711 | 0.86 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL18597115 | 0.86 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL28292434 | 0.86 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL16431121 | 0.86 | CES2 (0.59) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL18751717 | 0.85 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL9973396 | 0.85 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL9973392 | 0.85 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL26203820 | 0.85 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800827-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190092833-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800827-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | CES2 2734/4885MEN1 2494/4885FAAH 2626/4885 |
| US-20190092833-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | CES2 2734/4885MEN1 2494/4885FAAH 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.